SNORD114-22: A Potential Drug Target and Biomarker for Various Diseases

Target Name: SNORD114-22

NCBI ID: G767600

SNORD114-22

Other Name(s): 14q(II-22) | small nucleolar RNA, C/D box 114-22 | Small nucleolar RNA, C/D box 114-22

SNORD114-22: A Potential Drug Target and Biomarker for Various Diseases

SNORD114-22 is a non-coding RNA molecule located on chromosome 14q21.2. It is a part of the non-coding RNA gene family 114 and is also known as HSP70A2. This gene has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The HSP70A2 gene is a member of the heat shock protein (HSP) family, which are known to play a crucial role in the regulation of protein synthesis and can be activated in response to various stressors, such as infection, UV radiation, and chemotherapy. The HSP70A2 gene is expressed in various tissues and cells and has been shown to be involved in various cellular processes, including cell survival, apoptosis, and inflammation.

Studies have suggested that HSP70A2 may be a potential drug target for various diseases, including cancer. One of the reasons for this is the high expression of HSP70A2 in cancer cells, which may contribute to their resilience to chemotherapy and radiation therapy. Additionally, HSP70A2 has been shown to be involved in the regulation of cell cycle progression, which is a critical step in the development and progression of cancer. Therefore, targeting HSP70A2 may be a promising strategy for the development of new cancer therapies.

Another potential application of HSP70A2 as a drug target is its role in neurodegenerative diseases. neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and are often treated with neuroprotective drugs. However, the underlying causes of these diseases are not well understood, and targeting HSP70A2 may provide new insights into their pathophysiology.

In addition to its potential as a drug target, HSP70A2 has also been identified as a potential biomarker for various diseases. The HSP70A2 gene has been shown to be downregulated in various diseases, including neurodegenerative diseases, cancer, and autoimmune disorders. Therefore, measuring the expression of HSP70A2 may be a useful diagnostic tool for these diseases. Additionally, HSP70A2 has been shown to be involved in the regulation of cellular processes that are relevant to the development and progression of diseases. Therefore, studying the function of HSP70A2 may provide new insights into the underlying causes of these diseases.

In conclusion, SNORD114-22 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. The HSP70A2 gene is involved in various cellular processes that are relevant to the development and progression of these diseases, including cell survival, apoptosis, and inflammation. Targeting HSP70A2 may be a promising strategy for the development of new therapies for these diseases. Additionally, HSP70A2 has been shown to be involved in the regulation of cellular processes that are relevant to the development and progression of diseases, which may provide new insights into their underlying causes. Further research is needed to fully understand the role of HSP70A2 as a drug target and biomarker for various diseases.

Protein Name: Small Nucleolar RNA, C/D Box 114-22

The "SNORD114-22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD114-22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets